Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aeGF in knee osteoarthritis
NCT06690710Phase 1Recruiting
- Sponsor
- Scarcell Therapeutics
- Start
- Aug 2025
- Primary completion
- Feb 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic engineered gingival fibroblasts in osteoarthritis (OA), sponsored by Scarcell Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 3 months. Started Aug 2025; status: recruiting.
02
Drugs
allogeneic engineered gingival fibroblasts
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06690710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690710.